ArticleTherapeutic advances in psychopharmacology2021
Current antipsychotic agent use and risk of venous thromboembolism and pulmonary embolism: a systematic review and meta-analysis of observational studies.
Article in Therapeutic advances in psychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- An umbrella review of adverse effects associated with antipsychotic medications: the need for complementary study designs.Neuroscience and biobehavioral reviews · 2023Pooled it
- Thromboembolic events with olanzapine: a systematic review integrating meta-analysis and FAERS database.Frontiers in cardiovascular medicine · 2026Review
- Case Report: Early onset pulmonary embolism following antipsychotic polypharmacy in an acute psychiatric setting.Frontiers in psychiatry · 2026Article
- Effects of Nursing Home Changes in Antipsychotic Use on Outcomes among Residents with Dementia.Journal of the American Medical Directors Association · 2025Observational
- Dispensed prescription medications and short-term risk of pulmonary embolism in Norway and Sweden.Scientific reports · 2024Article
- Sex-specific differences in the clinical profile among psychiatric patients with pulmonary Embolism: a hospital-based retrospective study.BMC pulmonary medicine · 2024Article
- Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study.BMJ (Clinical research ed.) · 2024Article
- Association of Antipsychotic Drugs with Venous Thromboembolism: Data Mining of Food and Drug Administration Adverse Event Reporting System and Mendelian Randomization Analysis.Journal of atherosclerosis and thrombosis · 2024Article
- Association of Antipsychotic Drugs with the Risk of Recurrent Venous Thromboembolism: A Retrospective Study of Data from a Japanese Inpatient Database.Drugs - real world outcomes · 2024Article
- Article
- Pulmonary embolism incidence among patient admitted under psychiatry department: a case-control study.Frontiers in psychiatry · 2024Article
- Antipsychotic drugs as a contributing factor of pulmonary embolism: A report of 4 cases.Radiology case reports · 2023Article
- Pulmonary embolism or COVID-19 pneumonia? A case report.Respirology case reports · 2023Article
- Antipsychotic drugs may contribute to venous thromboembolism - a case report and review literature.JRSM open · 2023Article
- New Antipsychotic Prescribing Continued into Skilled Nursing Facilities Following a Heart Failure Hospitalization: a Retrospective Cohort Study.Journal of general internal medicine · 2022Article
- Is there association of olanzapine and pulmonary embolism: A case report.Clinical case reports · 2022Article
- Management of Systemic Medical Emergencies Associated with Psychotropic Medications.Indian journal of psychiatry · 2022Article
- Clozapine-induced pulmonary embolism in a patient with no pre-existing risk factors: A case report.Clinical case reports · 2022Article
- Antipsychotics cardiotoxicity: What's known and what's next.World journal of psychiatry · 2021Review
- The role of lumateperone in the treatment of schizophrenia.Therapeutic advances in psychopharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntipsychotic agents (APS) are widely used drugs to treat psychotic symptoms and can effectively reduce both positive and negative symptoms of schizophrenia. For decades, some studies suggested that there is a relationship between using APS and the risk of venous thromboembolism (VTE) and pulmonary embolism (PE). However, results remain inconclusive.
methodThis review has been registered in International Prospective Register of Systematic Reviews (PROSPERO, ID: CDR42020155620). Relevant studies were identified among observational studies published up to 1 October 2019 in the databases MEDLINE, EMBASE, and Cochrane Library. Random or fixed-effects models were used to calculate the pooled odds ratio (OR).
resultsIn total, 28 observational studies were included. The results showed that compared with non-users, current APS users have significantly increased risks of VTE [OR 1.55 95% confidence interval (CI) 1.36, 1.76] and PE (OR 3.68, 95% CI 1.23, 11.05). Subgroup analyses suggested that new users were associated with a higher risk of VTE (OR 2.06, 95% CI 1.81, 2.35). For individual drugs, increased risk of VTE and PE was observed in taking haloperidol, risperidone, olanzapine, prochlorperazine but not in chlorpromazine, quetiapine or aripiprazole. However, careful interpretation is needed because of high heterogeneity among studies and scarce data.
conclusionThe present comprehensive meta-analysis further indicates a significantly increased risk of VTE and PE in current APS users compared with non-users. Subgroup analyses suggest that new users are more likely to develop VTE. However, due to significant heterogeneity among studies, conclusions should be considered with caution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.